Revance Therapeutics’ (RVNC) “Neutral” Rating Reiterated at Guggenheim

Revance Therapeutics (NASDAQ:RVNC)‘s stock had its “neutral” rating reiterated by stock analysts at Guggenheim in a report issued on Monday, Benzinga reports.

Other analysts also recently issued research reports about the company. Stifel Nicolaus dropped their price target on Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Friday. Piper Sandler cut their price objective on shares of Revance Therapeutics from $11.00 to $6.00 and set an “overweight” rating on the stock in a report on Friday. Mizuho cut their price objective on shares of Revance Therapeutics from $9.00 to $8.00 and set a “neutral” rating on the stock in a research report on Friday, May 10th. Needham & Company LLC reiterated a “buy” rating and set a $12.00 target price on shares of Revance Therapeutics in a research note on Friday. Finally, HC Wainwright decreased their price target on shares of Revance Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, May 13th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $11.89.

Revance Therapeutics Stock Performance

Shares of NASDAQ:RVNC traded up $3.06 during midday trading on Monday, reaching $6.59. The company’s stock had a trading volume of 57,366,742 shares, compared to its average volume of 2,272,356. The firm has a market capitalization of $688.32 million, a price-to-earnings ratio of -1.82 and a beta of 0.98. Revance Therapeutics has a fifty-two week low of $2.30 and a fifty-two week high of $20.38. The firm has a 50 day moving average price of $3.13 and a two-hundred day moving average price of $4.11.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.12. The business had revenue of $65.39 million during the quarter, compared to the consensus estimate of $66.30 million. The firm’s revenue for the quarter was up 20.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.80) EPS. As a group, research analysts anticipate that Revance Therapeutics will post -1.83 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in RVNC. Tower Research Capital LLC TRC raised its stake in shares of Revance Therapeutics by 626.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,823 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 5,884 shares during the last quarter. Quest Partners LLC acquired a new position in shares of Revance Therapeutics in the fourth quarter worth about $84,000. Certuity LLC acquired a new stake in shares of Revance Therapeutics in the 2nd quarter valued at about $26,000. Victory Capital Management Inc. bought a new stake in Revance Therapeutics during the fourth quarter valued at $93,000. Finally, HighPoint Advisor Group LLC acquired a new stake in shares of Revance Therapeutics during the 4th quarter worth approximately $98,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.